Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Barnett

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Virology|October 13, 2017
HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same VaccineErin P McGuire, Youyi Fong, Christopher Toote, et al.
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
Plos One|February 24, 2012
Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsJuan Pablo Jaworski, Shelly J Krebs, Maria Trovato, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2007
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boostPrasert Thongcharoen, Vinai Suriyanon, Robert M Paris, et al.
Journal of Virology|June 16, 2005
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteinsGillis R Otten, Mary Schaefer, Barbara Doe, et al.
Virology|October 25, 2008
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challengeWilly M J M Bogers, David Davis, Ilona Baak, et al.
Cell Reports|January 4, 2016
Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding SiteTodd Bradley, Daniela Fera, Jinal Bhiman, et al.
Journal of Virology|November 16, 2018
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVACKaren V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|October 17, 2019
Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"Karen V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|April 19, 2013
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milkGenevieve G A Fouda, Joshua D Amos, Andrew B Wilks, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Virology|October 13, 2017
HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same VaccineErin P McGuire, Youyi Fong, Christopher Toote, et al.
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
Plos One|February 24, 2012
Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsJuan Pablo Jaworski, Shelly J Krebs, Maria Trovato, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2007
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boostPrasert Thongcharoen, Vinai Suriyanon, Robert M Paris, et al.
Journal of Virology|June 16, 2005
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteinsGillis R Otten, Mary Schaefer, Barbara Doe, et al.
Virology|October 25, 2008
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challengeWilly M J M Bogers, David Davis, Ilona Baak, et al.
Cell Reports|January 4, 2016
Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding SiteTodd Bradley, Daniela Fera, Jinal Bhiman, et al.
Journal of Virology|November 16, 2018
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVACKaren V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|October 17, 2019
Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"Karen V Kibler, Benedikt Asbach, Beatriz Perdiguero, et al.
Journal of Virology|April 19, 2013
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milkGenevieve G A Fouda, Joshua D Amos, Andrew B Wilks, et al.
Pageof 4